Profile data is unavailable for this security.
About the company
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
- Revenue in USD (TTM)484.44k
- Net income in USD-9.00m
- Incorporated2014
- Employees21.00
- LocationBiodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
- Phone+44 123 584 1575
- Websitehttps://www.biodexapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 5.29m | 24.00 | -- | -- | -- | 0.3716 | -3.11 | -3.11 | 1.44 | 0.005 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.38m | 4.00 | -- | 0.5414 | -- | 0.6715 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 5.42m | 12.00 | -- | 1.77 | -- | 58.40 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.47m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
Biodexa Pharmaceuticals PLC-ADR | 484.44k | -9.00m | 5.61m | 21.00 | -- | 0.64 | -- | 11.59 | -23.95 | -23.95 | 0.9338 | 2.00 | 0.0474 | -- | 0.4638 | 23,068.72 | -88.12 | -69.02 | -164.67 | -88.49 | -- | -- | -1,858.01 | -1,926.06 | -- | -- | 0.0902 | -- | -45.49 | -27.77 | 7.54 | -- | 1.51 | -- |
ProtoKinetix, Inc. | 0.00 | -400.47k | 5.65m | 0.00 | -- | 14.23 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Virios Therapeutics Inc | 0.00 | -5.07m | 5.65m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
Halberd Corp | 281.24k | 25.34k | 5.66m | 3.00 | 3.84 | -- | 223.07 | 20.12 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
HST Global Inc | 0.00 | -146.22k | 5.67m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Azitra Inc | 572.70k | -12.40m | 5.77m | 10.00 | -- | 1.33 | -- | 10.07 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
Biofrontera Inc | 33.25m | -23.09m | 5.80m | 85.00 | -- | -- | -- | 0.1745 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 5.81m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Kineta Inc | 5.16m | -17.89m | 5.83m | 11.00 | -- | -- | -- | 1.13 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Hoth Therapeutics Inc | 0.00 | -7.70m | 5.87m | 2.00 | -- | 0.6747 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
Healthy Extracts Inc | 2.49m | -2.47m | 5.93m | -- | -- | 6.19 | -- | 2.38 | -0.8588 | -0.8588 | 0.8611 | 0.3231 | 0.918 | 0.4921 | 36.50 | -- | -91.32 | -53.78 | -174.02 | -146.65 | 65.90 | 45.68 | -99.48 | -87.53 | 0.1636 | -9.72 | 0.5245 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
GAMMA Investing LLCas of 31 Mar 2024 | 11.10k | 4.23% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 5.24k | 2.00% |
Cavalry Fund I Management LLCas of 31 Dec 2023 | 2.77k | 1.06% |
UBS Securities LLCas of 31 Mar 2024 | 2.44k | 0.93% |
RhumbLine Advisers LPas of 31 Mar 2024 | 498.00 | 0.19% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 16.00 | 0.01% |
Boothbay Fund Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |